Johnson & Johnson Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries, Amount (Deprecated 2011-01-31)
Johnson & Johnson (JNJ) reported Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries, Amount (Deprecated 2011-01-31) of $61.59 billion for the 12-month period ending 2011-01-02, per its 10-K filed 2011-02-25.
Discontinued › Income Statement › Other Income
us-gaap:EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToIndividualForeignCountriesAmount · last filed 2011-02-25
- Johnson & Johnson entity-wide disclosure on geographic areas, revenue from external customers attributed to individual foreign countries, amount (deprecated 2011-01-31) for fiscal 2011 was $61.59B, a 0.50% decline from fiscal 2010.
- Johnson & Johnson entity-wide disclosure on geographic areas, revenue from external customers attributed to individual foreign countries, amount (deprecated 2011-01-31) for fiscal 2010 was $61.90B, a 2.90% decline from fiscal 2008.
- Johnson & Johnson entity-wide disclosure on geographic areas, revenue from external customers attributed to individual foreign countries, amount (deprecated 2011-01-31) for fiscal 2008 was $63.75B.
| Period end | Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries, Amount (Deprecated 2011-01-31) 12 month |
|---|---|
| 2011-01-02 | $61.59B 10-K · filed 2011-02-25 |
| 2010-01-03 | $61.90B 10-K · filed 2011-02-25 |
| 2008-12-28 | $63.75B 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |